New York Sues 3M, DuPont and Others Over PFAS Contamination in Consumer Products

New York Attorney General Letitia James filed a civil lawsuit in Albany state court against 3M, DuPont, Chemours, Corteva, and EIDP — the last three being former DuPont subsidiaries created through corporate spinoffs — over their manufacture and sale of per- and polyfluoroalkyl substances, commonly called PFAS or "forever chemicals."

The suit, reported by CNBC, alleges the companies created a public nuisance by knowingly selling PFAS-containing products while hiding the chemicals' environmental and health risks from consumers. Some of those companies had already begun quietly phasing certain PFAS out of their product lines.

What James Is Asking For

James is seeking a court order requiring the defendants to fund contamination cleanup, issue proper consumer warnings about PFAS risks, and pay damages, restitution, and other penalties. She has NOT announced a specific dollar figure publicly.

"For far too long, our communities have unfairly shouldered the costs of protecting people from these toxic forever chemicals and cleaning up their contamination," James said in a statement. "I look forward to ensuring the companies responsible for PFAS pollution are held accountable."

None of the defendants had responded to requests for comment as of the report's publication.

What PFAS Actually Are

PFAS are a class of synthetic chemicals found in hundreds of consumer and commercial products: non-stick cookware, stain-resistant clothing, cosmetics, and food packaging, among others. They are called "forever chemicals" because they resist breakdown in both the human body and the environment, meaning exposure accumulates over time.

The health effects tied to PFAS exposure include higher cholesterol levels, low birth weight, reduced antibody response to vaccines, and elevated risk of kidney and testicular cancer, according to existing scientific literature cited in the case.

The Legal Theory and Its Limits

The lawsuit rests on a public nuisance theory. Essentially, the companies' conduct created a widespread harm that the state and its residents are being forced to pay to address. That legal theory has had mixed results in similar mass-tort cases. Opioid manufacturers faced comparable claims, with some settling for billions and others successfully defending in court.

These are allegations made in a complaint filed by the Attorney General's office. None of the claims have been tested or proven before a judge or jury. The companies have NOT been found liable for anything as of July 9, 2026.

The Strongest Defense the Companies Will Likely Raise

The companies will almost certainly argue that PFAS were manufactured and sold in compliance with federal regulations at the time, that the science on health harms was contested or emerging during the periods in question, and that product liability for chemicals used lawfully across an entire industry should not rest solely on individual manufacturers. They may also argue that the state's cleanup costs, if any are attributable at all, cannot be traced specifically to their products versus the thousands of other PFAS sources in commerce.

Courts have thrown out similar cases when plaintiffs couldn't establish direct causation between a specific company's product and a specific harm. New York will need to do more than point to an industry-wide problem. It will need to connect specific defendants to specific contamination.

Why This Case Has Momentum

PFAS litigation has been building for years across the country, with manufacturers facing mounting legal pressure from states, municipalities, and individuals over contamination linked to their products.

New York's lawsuit is a state-level action targeting consumer products broadly, not just drinking water. That wider scope is deliberate. PFAS exposure doesn't begin and end at the tap.

The Open Question

The core unresolved issue in this case is whether New York can sustain the "concealment" theory — that the companies actively hid what they knew. If internal company documents show executives understood the risks and chose not to disclose them, that changes the litigation dramatically. If the state can't produce that paper trail, the case becomes a harder fight over regulatory compliance and evolving science rather than deliberate corporate wrongdoing. Discovery will determine which story the evidence tells.